Format

Send to

Choose Destination
J Thorac Dis. 2019 Jan;11(Suppl 1):S3-S8. doi: 10.21037/jtd.2018.12.03.

Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology.

Author information

1
Institute of Pathology, University Hospital Cologne, Cologne, Germany.
2
Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany.
3
Network Genomic Medicine, Cologne, Germany.
4
Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany.
5
Center for Integrated Oncology Cologne Bonn, Cologne, Germany.

Abstract

One distinct molecular subtype of non-small cell lung cancer (NSCLC) is defined by rearrangement of the anaplastic lymphoma kinase (ALK). The increasing knowledge over the last years has enabled the continuous improvement of ALK inhibitors; however, resistance in these patients remains a major concern. In this review, we summarize recent findings in ALK+-adenocarcinoma of the lung, highlighting the role of TP53 mutations in this specific cancer type and suggest new diagnostic strategies for the future, in order to improve patient's outcome.

KEYWORDS:

ALK+-adenocarcinoma; Non-small cell lung cancer (NSCLC); TP53; anaplastic lymphoma kinase (ALK); biomarker

Conflict of interest statement

Conflicts of Interest: J Wolf declares advisory boards and lecture fees from Abbvie, AstraZeneca, BMS, Boehringer-Ingelheim, Chugai, Ignyta, Lilly, MSD, Novartis, Pfizer, Roche; research support (to institution) from BMS, MSD, Novartis, Pfizer. R Buettner is a founder and Chief Scientific Advisor for Targos, Mol Pathol, Kassel, Germany. The other authors have no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center